12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation
Completed · Phase 2
Conditions studied: Smoking Cessation
In brief
The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019
Key facts
- Study ID
- NCT00150228
- Run by
- Pfizer
- People needed
- 300
- Starts
- 2001-12-01
- Expected to finish
- 2002-09-01
- Last updated by the study team
- 2007-06-04
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects must have smoked an average of at least ten cigarettes per day during the past year
- No period of abstinence greater than three months in the past year
You may not qualify if…
- Subjects with history of clinically significant cardiovascular disease
- Subjects with uncontrolled hypertension.
Where it is running
- Pfizer Investigational Site — Lexington, Kentucky, United States
- Pfizer Investigational Site — Albert Lea, Minnesota, United States
- Pfizer Investigational Site — Rochester, Minnesota, United States
- Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
- Pfizer Investigational Site — Providence, Rhode Island, United States
- Pfizer Investigational Site — La Crosse, Wisconsin, United States
- Pfizer Investigational Site — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.